ReLiSyR-MND

Repurposing Living Systematic Review - Motor Neuron Disease. A @CAMARADES_ and @MNDSMART project to improve drug selection for MND clinical trials.

[ReLiSyR-MND @RelisyrMND]

Hello Twitter! 👋 @RelisyrMND is a @CAMARADES_ and #MNDSMART project aiming to improve how drugs are selected for MND clinical trials. We review published clinical studies, animal studies and cell studies in MND and other neurodegenerative diseases.

[Charis Wong (chariswong.bsky.social) @DrCharisWong]

Our manuscript detailing a systematic evidence-based approach towards drug selection for the first 2 arms of @mndsmart is now available @BMJ_Open. Many thanks to the large team behind this @CAMARADES_ @RelisyrMND @EdinUniBrainSci @EuansCentre https://t.co/GMU6UjxKGA

[Charis Wong (chariswong.bsky.social) @DrCharisWong]

Thank you! Delighted to share our work on developing a data-driven framework for #MND clinical trials at #ENCALS2022. I will be at poster i189 in the marquee during the poster session if anyone would like to come along and chat.

[Charis Wong (chariswong.bsky.social) @DrCharisWong]

Fantastic two days in London. Great to meet the expanding @mndsmart team in person and hear about the excellent work across the 17 sites, and share our work on developing a data-driven framework for drug selection. @EuansCentre @CAMARADES_ @Maclomaclee @RelisyrMND

[Charis Wong (chariswong.bsky.social) @DrCharisWong]

Our #ENCALS2022 poster on developing a data-driven framework for drug selection in #MND clinical trials now available on https://t.co/yXGr4hGMYZ @suvankarpal @bhuvaneish @Maclomaclee @mndsmart @EuansCentre @CAMARADES_ @RelisyrMND @EdinUniBrainSci

[Evidence Synthesis Hackathon @eshackathon]

NOW: Charis Wong (@DrCharisWong) - Developing a systematic framework to identify, evaluate and report evidence for drug selection in motor neuron disease clinical trials

#EvidenceSynthesis #MetaAnalysis #RStats #ReviewProcesses

https://t.co/oNLv2bd9lG

[ReLiSyR-MND @RelisyrMND]

@suvankarpal @mndsmart @EdinUniNeuro Exciting to hear progress on @mndsmart and interest on how we hope to use different types of data (systematic reviews, drug screening, pathway analysis) to inform future drug selection. More info 🧵👇: https://t.co/FoZxCD0eA7

[ReLiSyR-MND @RelisyrMND]

Hello Twitter! 👋 @RelisyrMND is a @CAMARADES_ and #MNDSMART project aiming to improve how drugs are selected for MND clinical trials. We review published clinical studies, animal studies and cell studies in MND and other neurodegenerative diseases.

[CAMARADES @CAMARADES_]

We are excited to announce the launch of the Edinburgh University Research Optimisation Course (EUROC) 🎉 the course is open to all and covers rigorous design, conduct, analysis and reporting of research using animals https://t.co/79MfqY50I6

[ReLiSyR-MND @RelisyrMND]

The replication crisis – why so many drugs which are promising in the lab are ineffective in clinical trials – and a ‘Publomics’ approach to tackling this. Embodies why we, @RelisyrMND, do what we do and how we hope to do better in motor neuron disease.

[Malcolm Macleod #FBPE @Maclomaclee]

An “Omics” Answer to the Replication Crisis https://t.co/6x3ohQbdgk

[ReLiSyR-MND @RelisyrMND]

Congratulations to our reviewer of the month for March 2021: @ainebheffernan! Thank you for all your work on the project. Here's what Áine has to say about her experience on @RelisyrMND:

[Malcolm Macleod #FBPE @Maclomaclee]

Just out - in which we describe the nuts and bolts that make up the SyRF platform @camarades_ @ZsanettBahor @Nadia_Soliman_ @ABannachBrown @kweverten @drEmilySena and first senior author paper (I think) for @Chrissena87 https://t.co/gR5JwKqvTC

[ReLiSyR-MND @RelisyrMND]

@CAMARADES_ @mndsmart @EuansCentre @Maclomaclee

[ReLiSyR-MND @RelisyrMND]

Our reviewers have been hard at work!

We're now at
471 single annotated
479 dual annotated
for the clinical review.

That's a total of 2⃣4⃣2⃣ papers annotated in the past month!

Thank you team, fantastic effort

[ReLiSyR-MND @RelisyrMND]

Progress stats

Clinical review:
20770 publications identified ->
6363 included ->
1067 describing our trialists' drugs of interest, of which:
591 single annotated
298 dual annotated
24 reconciled

Animal in vivo review - all papers for drugs of interest dual annotated!

[ReLiSyR-MND @RelisyrMND]

Congratulations to our reviewer of the month for February: Yu Cheng Foo @ed_in_edin99 👏👏 Yu Cheng annotated a total of 77 papers for the @RelisyrMND project. Thank you! Here's what Yu Cheng has to say about ReLiSyR:

[MND-SMART @mndsmart]

MND-SMART is a new type of clinical trial. It is designed to speed up the time it takes to find new treatments for #MND #ALS. https://t.co/DYgDv24SYu

[MND-SMART @mndsmart]

Hello Twitter. Looking forward to sharing information, updates and news about the #MND-SMART trial from @EuansCentre kindly funded by @EuansCentre @MNDScotland @MNDoddie5

[ReLiSyR-MND @RelisyrMND]

This work is only possible with teamwork, collaboration and innovation. Many thanks to our fantastic team of reviewers 👏

[ReLiSyR-MND @RelisyrMND]

Progress stats

Clinical review:
20770 publications identified ->
6363 included ->
1067 describing our trialists' drugs of interest, of which:
591 single annotated
298 dual annotated
24 reconciled

Animal in vivo review - all papers for drugs of interest dual annotated!

[ReLiSyR-MND @RelisyrMND]

Our @RelisyrMND reviewer of the month is Jiaming Liu. 👏👏Jiaming is a 4th year medical student @EdinUniMedicine. Here's a little note about ReLiSyR-MND from Jiaming:

[ReLiSyR-MND @RelisyrMND]

For unclear reasons, the tweet pictured seems to be appearing as unavailable on Twitter. SyRF is vital for our project; also available as a free to use resource for researchers.

[ReLiSyR-MND @RelisyrMND]

Hello Twitter! 👋 @RelisyrMND is a @CAMARADES_ and #MNDSMART project aiming to improve how drugs are selected for MND clinical trials. We review published clinical studies, animal studies and cell studies in MND and other neurodegenerative diseases.

[ReLiSyR-MND @RelisyrMND]

Follow us for updates on our reviews, learn more about our reviews and our teams. 😀